~~<i id='29F544A669'><strike id='29F544A669'><tt id='29F544A669'><pre id='29F544A669'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：Wikipedia 2025-09-07 17:20:39 - browse：7626

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Medicare Advantage today, explained in one chart

focus

leisure time

focus

hotspot

SpencerPlatt/GettyImagesHigherrankingmilitaryofficersreceivemoreresourcesandbettercarethanlowranking

WSS

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Independent physicians launch a new lobbying group

Data integrity in scientific journals requires "effort" by publishers, institutions

NIH director takes cautious approach to Biden drug pricing priority

How digital therapeutics firms are pivoting after Pear's bankruptcy

focus

Wikipedia

focus

How one medical school became remarkably diverse

NIH director takes cautious approach to Biden drug pricing priority

Novavax promises a turnaround & Lilly roils the obesity market

Francis Collins on trust in science and how Covid communications failed

United colonoscopy coverage change 'may cost lives,' doctors say

Independent physicians launch a new lobbying group

Medicare proposal to cover medical devices draws a mixed reaction

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Merck, J&J, and long Covid

focus

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Arc Institute generative AI designs new CRISPR systems

Glen Campbell's doctor discusses his public struggle with Alzheimer's

AI generated plenty of interest at JPM but not a lot of trust

Dewpoint Therapeutics lays off staff after losing partnerships

Copay coupons to count toward deductibles, after Biden court move

focus

leisure time

focus

hotspot